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Background: Peripheral neuroblastic tumors (pNTs), including neuroblastoma (NB), ganglioneuroblastoma (GNB)
and ganglioneuroma (GN), are extremely heterogeneous pediatric tumors responsible for 15 % of childhood cancer
death. The aim of the study was to evaluate the expression of CD44s (‘s’: standard form) cell adhesion molecule by
comparison with other specific prognostic markers.
Methods: An immunohistochemical profile of 32 formalin-fixed paraffin-embedded pNTs tissues, diagnosed
between January 2007 and December 2010, was carried out.
Results: Our results have demonstrated the association of CD44s negative pNTs cells to lack of differentiation and
tumour progression. A significant association between absence of CD44s expression and metastasis in human pNTs
has been reported. We also found that expression of CD44s defines subgroups of patients without MYCN
amplification as evidenced by its association with low INSS stages, absence of metastasis and favorable Shimada
histology.
Discussion: These findings support the thesis of the role of CD44s glycoprotein in the invasive growth potential of
neoplastic cells and suggest that its expression could be taken into consideration in the therapeutic approaches
targeting metastases.
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vs/1034403150888863Résumé
Introduction: les tumeurs neuroblastiques périphériques (TNPs), comprenant le neuroblastome (NB), le
ganglioneuroblastome (GNB) et le ganglioneurome (GN), sont des tumeurs pédiatriques extrêmement hétérogènes
responsables de 15% des décès par cancer chez les enfants. Le but de cette étude était d’évaluer l’expression de la
molécule d’adhésion cellulaire CD44s (‘s’: pour standard) par rapport à d’autres facteurs pronostiques spécifiques.
Méthodes: Un profil immunohistochimique de 32 TNPs fixées au formol et incluses en paraffine, diagnostiquées
entre Janvier 2007 et Décembre 2010, a été réalisé.
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Résultats: Nos résultats ont mis en évidence l’association des TNPs n’exprimant pas le CD44s avec une perte de
différenciation et une progression tumorale et nous avons rapporté une association significative entre l’absence
d’expression du CD44s et la présence de métastases. Nous avons également constaté que l’expression du CD44s
définit des sous-groupes de patients dans les tumeurs n’amplifiant pas le MYCN, comme en témoigne son
association avec les stades INSS bas, l’absence de métastases et l’histologie favorable de Shimada.
Discussion: Ces résultats appuient l’hypothèse du rôle de la glycoprotéine CD44s dans le potentiel de croissance
invasive des cellules néoplasiques et suggèrent que son expression pourrait être prise en considération dans des
voies thérapeutiques ciblant les métastases.
Mots-clés: CD44s, Métastases, Immunohistochimie, Marocain, Tumeurs neuroblastiques périphériques, PronosticIntroduction
Peripheral neuroblastic tumors (pNTs) are a generic
term including neuroblastoma (NB), ganglioneuroblastoma
(GNB), and ganglioneuroma (GN). These embryonic
tumors, which account for 15% of childhood cancer fatal-
ities, are derived from immature sympathetic neuroblasts
and diagnosed in the primary sites related to the distribu-
tion of neural crest cells, such as adrenal medulla and
structures of the sympathetic nervous system in the thorax,
abdomen, and pelvic cavity [1].
The most benign tumor is the ganglioneuroma, which
is composed of gangliocytes and mature Schwannian
stroma. Ganglioneuroblastoma is composed of both ma-
ture gangliocytes and immature neuroblasts and has
intermediate malignant potential. Neuroblastoma is the
most immature, undifferentiated, and malignant tumor
of the three [2].
These tumors are well known to show unique and
often unpredictable clinical behaviors. Recent advances
have led to the belief that the pNTs are heterogeneous
and contain biologically different tumors. The biologic-
ally favorable tumors have a potential of involution/
spontaneous regression or tumor maturation with or
without chemotherapy/irradiation therapy. In contrast,
the biologically unfavorable tumors progress aggressively
and often bring a fatal outcome to the patients despite
intensive treatment [3].
The International Neuroblastoma Pathology Classifica-
tion (INPC), based on the Shimada classification system
adopted in 1999 [4,5] and revised on 2003 [6], distinguishes
favorable and unfavorable tumors depending on the age at
diagnosis, the amount of Schwannian stromal content, the
degree of neuroblastic differentiation and the mitosis-
karyorrhexis index (MKI) [7].
In addition to the modified Shimada classification [8],
other specific markers, alone or in combination, can help
to stratify disease by adding prognostic significance to
pNTs. At the moment, stratification is based on clinical
features: age at diagnosis (children older than 18 months
have a better prognosis compared to infants) [9] and
International Neuroblastoma Staging System (INSS)classification (patients with localized tumors have an ex-
cellent outcome) [10]. Genetic features are also involved
in these tumors, the most independent prognostic factor
being the MYCN proto-oncogene status: hence, MYCN
amplification (≥10 copies) is highly correlated to very ag-
gressive disease [11] whereas copy number gain (1–9 co-
pies more than chromosome 2 centromer signals) is
recently reported to correlate with good outcome; indeed,
Zhou et al. demonstrated in a very recent study (2013)
that patients with MYCN gain tumors had a better prog-
nosis than those presenting MYCN amplification and even
those with MYCN gene normal copy number) [12]. Other
biological characteristics having a prognostic value such as
TrkA expression (TrkA is expressed at high levels in bio-
logically favorable neuroblastomas) [13], ploidy (in some
groups of children with NB, near-triploid DNA content
tumors are prognostically favorable in contrast to tumors
with a near-diploid DNA content) [14] and chromosomal
abnormalities (tumors harboring segmental chromosome
alterations (1p and 11q losses or 17q gain) are consider-
ably worse than those with only numerical chromosome
aberrations (whole chromosome gains or losses) [15-17],
have also been detailed in pNTs tumors.
CD44 is an adhesion molecule with binding domains for
hyaluronic acid (HA), an abundant and crucial component
of the extracellular matrix, and other glycosaminoglycans
such as collagen, laminin and fibronectin [18,19]. CD44
comprises a family of glycoproteins that are encoded by 20
exons of a single gene located at the short arm of chromo-
some 11 [20]. The size of the molecule varies between 80
and 200 kDa. This size heterogeneity is due to the variable
N- and O-linked glycosylation and to alternative splicing
that allows the insertion of the so-called variable exon
products (CD44 v) in the extracellular, membrane pro-
ximal region of the molecule [20]. The smallest CD44
molecule, which lacks the entire variable region, is stand-
ard CD44 (CD44s). As it is expressed mainly on cells of
lymphohematopoietic origin, CD44s is also known as
hematopoietic CD44 (CD44H). This standard isoform is
present on the membrane of most vertebrate cells [18]. In
contrast, expression of isoforms including some variants,
Tabyaoui et al. Diagnostic Pathology 2013, 8:39 Page 3 of 9
http://www.diagnosticpathology.org/content/8/1/39characterizes rapid renewal tissues such as skin [20]. CD44
cell surface transmembrane glycoprotein has been involved
in many cellular processes which include lymphocyte acti-
vation, recirculation and homing, adhesion of extracellular
matrix, angiogenesis, cell proliferation, cell differentiation
and cell migration [21,22]. CD44 is highly expressed in
many malignancies and is correlated with the tumor bio-
logical behavior including tumorigenesis, growth, metas-
tasis and prognosis [23]. It is a reliable indicator of
tumor load and disease activity; it is also called metasta-
sis associated protein. Many correlative studies have
revealed pronounced expression of CD44 in human
tumors, and in some, such as colon cancer, clear cell
carcinoma of the kidney or hematological malignancies,
the expression of some variants has a poor prognosis
[24-26]. Conversely, the degree of malignancy of some
cancers such as prostate cancer, is associated with loss of
CD44 [27], suggesting that CD44 could be a tumor sup-
pressor. CD44 is, therefore, an attractive biologic marker
for analysis in tumors. In addition, the evaluation of its ex-
pression by immunohistochemistry is a simple, fast and re-
liable standardized method. The aim of this study was to
assess retrospectively the clinical relevance of CD44s cell-
surface expression in a series of human peripheral
neuroblastic tumors and to correlate this expression with
other clinical, histological and biological features character-
izing these pNTs. There was also an attempt to report the
current data concerning this cancer-initiating cell.
Materials and methods
This retrospective study was performed on 32
formalin-fixed paraffin-embedded pNTs (neuroblastoma,
ganglioneuroblastoma and ganglioneuroma) archival ma-
terial collected from the Pathology Department of the “Ibn
Rochd” Hospital. Tissue specimens corresponded to cases,
diagnosed between January 2007 and December 2010, with
clinical data was retrieved from the files of the Department
of Pediatric Oncology and Hematology of the “20
Août 1953” Hospital and from the Departments of
Pediatric Visceral Surgery and Pediatrics III of the
“Harouchi” Children’s Hospital. These three hospitals
form the “Ibn Rochd” University Medical Center of
Casablanca, Morocco.
Patients were classified according to the INSS classi-
fication that classified pNTs into five stages in terms
of the clinical presentation and age. Briefly, stages I
and II are localized tumors, stage II with ipsilateral
lymph node involvement. Stage III tumors infiltrate
across the midline or show contralateral lymph node
involvement. Stage IV is metastatic disease. Stage IVs
(“s” for special), corresponding to localized tumors
with a special pattern of liver, skin and/or minimal
bone marrow metastasis (without bone involvement), is
restricted to infants (under 1 year). Stages I, II and IVsare considered favorable, whereas stages III and IV are
associated with poor prognosis.
Histopathological review
After the morphological examination of the hematoxylin
and eosin (H&E) stained slides of the untreated pNTs,
the tumors were classified in accordance with the
INPC (Shimada system). This system classifies the
tumors based on the amount of Schwannian stroma into
three categories: neuroblastomas are stroma-poor;
ganglioneuroblastomas are stroma-rich (GNB intermixed)
or stroma-poor and stroma-rich/dominant (GNB nodular)
and ganglioneuromas are stroma-dominant.
Based on the proportion of differentiating neuroblasts
(the degree of neuroblastic maturation toward ganglion
cells) and the presence or absence of neuropil (thin neuritic
processes), the neuroblastomas can be subdivided into
three subtypes. Undifferentiated neuroblastomas show no
signs of maturation; they contain less than 5% differentiated
neuroblasts and no neuropil. The poorly differentiated
neuroblastomas also contain less than 5% differentiating
neuroblasts; they differ from the undifferentiated tumours
by the distinct presence of neuropil among the tumor cells.
Schwannian stroma-poor tumors containing more
than 5% differentiating neuroblasts are classified as
differentiating neuroblastomas.
The ganglioneuroblastomas are divided into two
subtypes: Ganglioneuroblastoma intermixed is a stroma-
rich tumour with microscopic well defined nests of
neuroblasts in different stages of maturation as well as
varying numbers of maturing ganglion cells found in the
background of neuropil. Ganglioneuroblastoma nodular
has a macroscopically visible well-demarcated nodule of
stroma-poor neuroblastic tissue in an otherwise stroma-
rich or stroma-dominant tissue composed of maturing
ganglion cells. Ganglioneuroma mature is the completely
mature lesion, containing only mature ganglion cells and
Schwannian stroma.
Three MKI classes (low: 2% or 100 of 5000 mitotic and
karyorrhectic cells; intermediate: 2-4 % or 100–200 of 5000
mitotic and karyorrhectic cells and high: 4% or 200 per
5000 mitotic and karyorrhectic cells) were distinguished.
According to Shimada classification, pNTs were placed ei-
ther in the favourable histology (FH) or the unfavourable
histology (UH) category. Table 1 summarizes the classifica-
tion according to Shimada.
CD44s expression by immunohistochemistry
Briefly, 4 μm thick sections were cut from the formalin-
fixed, paraffin-embedded specimens and placed on
treated slides. After having been heated at 60°C for 30 min,
then at 37°C overnight, the tissue sections were dewaxed
in toluene for 10 min, three times each, rehydrated in etha-
nol for 10 min, three times each, and rinsed once in
Table 1 The distribution of tumor subtypes
Subtypes n = 32
Undifferentiated neuroblastoma 7
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enhanced by pretreatment for 30 minutes at 99°C in citrate
buffer (pH 6). After 20 minutes cooling at room
temperature, endogenous peroxidase was quenched with
H2O2 for 10 min. Sections were then incubated with
monoclonal primary antibody for 30 min. Primary antibody
used in this study was anti-CD44-standard form (1:50
dilution) (clone DF1485, Dako). Immunobinding of anti-
CD44 was visualized with Dako REAL EnVision Detection
System, Peroxidase/DAB, Rabbit/Mouse (DAKO kit, Dako,
Glostrup, Denmark). Sections were counterstained with
Hematoxylin for 1–2 min and mounted with Eukitt.
Multiple Myeloma with known CD44s positivity
served as positive control.
Immunostaining assessment of CD44s expression
All of immunostained tissues were scored semi-
quantitatively by one author (N.T.J.) without the know-
ledge of the clinical and pathologic parameters of patients.
Obtained results were confirmed by two observers (N.T.J.
and S.Z.) on two separate occasions. In difficult cases, a
consensus was achieved using a multi-headed microscope.
Slides were first observed at 10 ×magnification to ob-
tain an impression of the overall distribution of the
neoplastic cells. Positive staining was then assessed
semi-quantitatively at higher magnifications. CD44 ex-
pression was considered positive if brown membrane
staining was found in more than 10% of neoplastic
cells. In almost all positive tumor samples, staining was
strong and uniform.
MYCN amplification status by fluorescence in situ
hybridization (FISH)
FISH was performed on formalin-fixed, paraffin-embedded
tissue. The sample that contained the most immature areas
was selected, particularly in GNB, which displayed hetero-
geneous maturation. FISH was performed using a commer-
cial Locus Specific Identifier (LSI) MYCN SpectrumGreen
DNA probe and an alpha satellite region chromosome
2-specific (CEP 2), SpectrumOrange DNA probe as an
internal standard. Sections 4 μm-thick were mounted on
SuperFrost slides. The sections were dewaxed in three
washes of toluene, followed by three washes in ethanolfor 10 min at room temperature. Slides were then
incubated for 15 min at 99°C in heat pretreatment solution,
pH7 (Zymed Laboratories, San Francisco, CA, USA), and
digested with enzyme reagent (Zymed Laboratories) at
37°C for 15 min. Each step was followed by two or three
washes with phosphate buffered saline (PBS) 10X. After
dehydration in a series of 70%, 90% and 100% ethanol for
2 minutes each at room temperature, 10 μl of probe
mixture which contained 1 μl of MYCN probe (LSI N-
MYC/CEP2, Vysis Abbott), 2 μl of purified H2O, and
7 μl of LSI hybridization buffer (Vysis, Abbott), were ap-
plied to each target area and slides were glass coverslipped
and sealed with RubberCement. Co-denaturation and
hybridization were proceeded with the HYBrite (Dako)
already programmed (co-denaturation for 5 min at 95°C
and hybridization overnight at 37°C). After removing the
coverslips, the slides were washed in 2X standard saline
citrate (SSC)/0.3% Igepal (Sigma-Aldrich, St. Louis, MO,
USA) at 75°C for 5 min and immersed twice in the
same solution at room temperature. After air drying
slides in darkness, the hybridization was visualized by
applying 12 μl of DAPI/Vectashield (Vector Laboratories)
mounting medium. The amplification of MYCN was
assessed by the number of fluorescent hybridization signals
within the nuclei of tumor cells. Tumor cells with more
than 10 copies of MYCN were considered as amplified.Statistical analysis
Statistical comparisons between subgroups were made
using the appropriate statistical test (Chi-square, Chi-
square with Yates correction or Chi square for linear
trend tests and Fisher exact test). For multivariate ana-
lysis, we used the logistic regression with stepwise likeli-
hood ratio test: (Forward: LR (Likelihood Ratio) Method
of covariate entry). The analysis was performed by SPSS
16.0 software. For all tests, P values lower than 0.05 were
considered statistically significant.Results
Clinical presentation
Thirty-two tumor specimens from newly diagnosed
peripheral neuroblastic tumors patients were collected
since 2007 during the 4-year period. The youngest pa-
tient was 9 days old, the oldest patient was 13 years
old (mean age at diagnosis 41 months). Most analyzed
cases, 21/32 (65.6%), were diagnosed among children
above 18 months of age. There were 22 (69%) boys
and 10 girls (31%), M:F = 2.2. Primary site of the
tumor was not detected for one patient. 28.1% of the
patients had low stage disease (6 INSS stages I/II and
3 INSS stage IV-s) whereas 71.9% had high stage (5 INSS
stage III and 18 INSS stage IV). In 71% of cases, tumors
were situated in the retroperitoneal space.
AB
Figure 1 CD44s expression on neuroblastoma cells:
A/membranous staining. B/cytoplasmic staining
(magnification x400).
Tabyaoui et al. Diagnostic Pathology 2013, 8:39 Page 5 of 9
http://www.diagnosticpathology.org/content/8/1/39Histopathology
All 32 pNTs were initially classified into four categories:
neuroblastoma (NB; Schwannian stroma-poor); gan-
glioneuroblastoma, intermixed (GNBi; Schwannian
stroma-rich); ganglioneuroma (GN; Schwannian stroma-
dominant); and ganglioneuroblastoma, nodular (GNBn;
composite, Schwannian stroma-rich/stroma-dominant
and stroma-poor). The distribution of tumor subtypes is
shown in Table 1.
Shimada prognostic grading
19 (59.4%) tumors showed unfavourable histology whereas
13 (40.6%) were classified into favorable histology. The
nodular ganglioneuroblastoma had neuroblastic nodules
with unfavorable histology and was included in this cat-
egory. 88.9% tumors with FH were localized (stage I, II or
IV-s). FH was associated with low clinical stage (P = 0.002).
The opposite was true for the tumors with UH, with only
11.1% localized while 78.3% widespread at diagnosis. UH
was associated with high clinical stages (stage III or IV)
(Table 2).
Estimation of prognostic value of CD44 cell-surface
expression in correlation with prognostic factors
and histoclinical features in neuroblastic group of
tumors
Positive CD44 immunostaining was observed on 18
samples (56%) (Figure 1). Essential correlations between
CD44 expression and histoclinical characteristics in the
neuroblastoma group of tumors are shown in Table 3.
No correlations between age at diagnosis or primary
sites of the disease and CD44 expression were observed
(P >0.05). All the low grade stages (I, II and IVs) were
CD44-positive. The significant correlation of CD44 ex-
pression with the stage of the disease strongly suggests
that it might help predict clinical outcome (P = 0.006).
Of the 32 tumors, 18 were undifferentiated, whereas
14 were classified as differentiated pNTs (ganglio-
neuroblastoma or ganglioneuroma). CD44 expression
was observed on 78.6% differentiated tumors, but only
on 38.9% of undifferentiated specimens (P = 0.025). In
contrast, only 21.4% differentiated tumors showed no
CD44-staining versus 61.1% undifferentiated cases. We
also observed a significantly statistical correlationTable 2 Prognostic types of neuroblastic tumors based on
the INPC in relation to INSS
Favorable histology Unfavorable histology P value
Low stages




5 (21.7) 18 (78.3)
(III, IV)
* Yates correction for continuity.between CD44 expression and Shimada’s histological
grading (P = 0.001): CD44s negative tumors are
associated with an unfavorable prognostic type.
The CD44 reactivity on tumor samples was significantly
correlated with the absence or presence of metastasis:
among cases with no metastases, 90.9% expressed CD44
against only 9.1% of cases CD44-negative (P = 0.013).
The expression of investigated CD44 protein was
compared with the above described selected histoclinical
and prognostic factors. The logistic regression model has
allowed identifying two variables associated with the ex-
pression of CD44, Shimada category and the presence of
metastases (Table 4). The patients without metastasis and
those of the FH group were more likely to express CD44.
CD44 expression and MYCN amplification status
Analysis of CD44 expression and MYCN status was
available for 31 children. Of 18 CD44-positive patients,
15 (83.3%) showed no MYCN amplification and only
3 (16.7%) were MYCN-amplified. In contrast, of 13
CD-44 negative patients, 6 (46.1%) showed no MYCN
amplification and 7 (53.9%) were amplified. However,
Table 3 Essential correlations between CD44 cell-surface












< 18 11 (34.4) 5 (45.5) 6 (54.5) 1*
≥ 18 21 (65.6) 9 (42.9) 12 (57.1)
Primary site
Retroperitoneal space 22 (71) 9 (40.9) 13 (59.1) 1*
Other sites 9 (29) 4 (44.4) 5 (55.6)
Metastasis
Presence 21 (65.6) 13 (61.9) 8 (38.1) 0.013*
Absence 11 (34.4) 1 (9.1) 10 (90.9)
INSS stages
I, II, IVs 9 (28.1) 0 (0.0) 9 (100.0) 0.006
III, IV 23 (71.9) 14 (60.9) 9 (39,1)
Differentiation
NB 18 (56.2) 11 (61.1) 7 (38.9) 0.025
GNB + GN 14 (43.8) 3 (21.4) 11 (78.6)
Shimada category
FH 13 (40,6) 1 (7.7) 12 (92.3) 0.001
UH 19 (59,4) 13 (68.4) 6 (31.6)
* Yates correction for continuity.
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Table 5 shows the results of the CD44 expression
stratified by the MYCN amplification status in rela-
tion to clinical and histopathological parameters. We
noted that when MYCN was non-amplified, CD44
expression was significantly associated with low INSS
stage (P = 0.046), absence of metastasis (P = 0.019)
and favorable INPC histology (P = 0.004). In contrast,
in MYCN-amplified tumors, no significant association
between CD44 expression and the other factors had
been demonstrated.
Discussion
In this first histopathological review of Morocco, we
have investigated the prognostic value of CD44 cell-
surface glycoprotein in 32 peripheral neuroblastic
tumors and its relationship to other known prognostic
indicators such as age at diagnosis, INSS stage of theTable 4 Results of multivariate analysis of CD44 expression
compared with histoclinical features
ORa P value
Metastasis 0.07 0.037
Shimada category 23.16 0.011
ORa: Adjusted odds ratio.disease, primary site, metastasis, differentiation and
modified Shimada system.
An earlier study by Combaret et al. showed that CD44
expression strongly correlated with patient’s age as it
was expressed on 61 of 66 tumors from infants (less
than 1 year of age), but only in 47 of 74 tumors from
older children (P < 0.0001) [28]. We were unable to dem-
onstrate such a correlation probably because of the high
mean age of our study cohort (41 months) while the fre-
quent median age of pNTs diagnosis is 22 months [29].
This disparity may be due to a delay in diagnosis caused
by difficulties in access to health care. Moreover, the
study of Combaret et al., achieved in 1997, had
investigated the CD44 expression compared to the 1 year
cut-off, while a recent study showed evidence for an age
cut-off (between 15 and 19 months) greater than 1 year
for use in risk stratification of neuroblastoma patients
[9]. So we definitely retained the threshold of 18 months
in our study.
Study achieved by Taran et al. did not find a clear
statistically significant correlation between CD44 expres-
sion and histoclinical parameters and currently known
prognostic factors; however, this study had reported
CD44 expression in 88.88% of cases and, unlike our
study, it has noticed that the strongest CD44 expression
was observed in tumors situated in the retroperitoneal
space [30].
As reported by several other studies [31,32], we found
that CD44 is down-regulated in advanced neuroblastomas
(stage III and IV), whereas the earlier and prognostically fa-
vorable stages (I, II, IVs) are characterized by tumor cells
maintaining their ability to synthesize the standard form of
CD44 (P = 0.006). This significant correlation of CD44 ex-
pression with the INSS stage strongly suggests that it might
help in the prediction of clinical outcome. In contrast, an-
other study demonstrated no major variation of CD44 inci-
dence throughout the stages, except for stage IVs (I-II-III:
84%, IVs: l00%, IV: 85%) [33]. We can then speculate that
CD44 might positively contribute to maturation and spon-
taneous regression of low grade stages I, II and IVs
neuroblastic tumors.
In our study, absence of CD44s expression correlated
significantly with a lack of differentiation (P = 0,0025). This
result was comparable with other studies on neuroblastic
tumors, indicating that the expression of CD44 standard
form is linked to tumor maturation and differentiation
[34,35]. These findings were supported by a study which
reported that cultured human neuroblastoma GOTO cells,
of which a cell adhesion molecule CD44 expression is
usually suppressed, could be induced to differentiate into
Schwannian cells and neuronal cells in the presence of
5-bromo-2’-deoxyuridine (BrdU) and by serum depletion
respectively. These GOTO cells differentiated into
Schwannian cells, specifically expressed CD44 glycoprotein,




P valueCD44 positive CD44 negative CD44 positive CD44 negative
No. (%) No. (%) No. (%) No. (%)
Age (months)
< 18 1 (20) 4 (80) 1** 4 (80) 1 (20) 1**
≥ 18 2 (40) 3 (60) 10 (66.7) 5 (33,3)
INSS stages
I, II, IVs 1 (100) 0 (0) 0,3 8 (100) 0 (0) 0,046
III, IV 2 (22.2) 7 (77,8) 7 (53.8) 6 (46,2)
Metastasis
Presence 2 (25) 6 (75) 1 6 (50) 6 (50) 0,019
Absence 1 (50) 1 (50) 9 (100) 0 (0)
Differentiation level
Undifferentiated 3 (30) 7 (70) - 5 (55.6) 4 (44.4) 0,33
Differentiated 0 (0) 0 (0) 10 (83.3) 2 (16.7)
Shimada category
Favorable histology 1 (50) 1 (50) 1 11 (100) 0 (0) 0.004
Unfavorable histology 2 (25) 6 (75) 4 (40) 6 (60)
MKI Index
High 1 (50) 1 (50) 0.645* 5 (71,4) 2 (28.6) 0.262*
Intermediate 0 (0) 2 (100) 2 (50) 2 (50)
Low 1 (25) 3 (75) 1 (33.3) 2 (66.7)
* chi square for linear trend.
** Fisher exact test.
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differentiated into neuronal cells which suggests that
CD44 might play an important role in GOTO cells differ-
entiation into Schwannian cells [36] and thus in tumor
evolution into maturing subtypes.
Our data analyzing the expression of CD44s in 32
neuroblastic tumours according to the INPC system
(modified Shimada grading), demonstrated that 92.3% of
CD44s-positive tumors were of a favorable prognostic
type based on the INPC (with a better event-free sur-
vival probability) versus 68.4% CD44s-negative tumors
in the unfavorable prognostic category (poorer event-
free survival probability) (P = 0,001). These data were in
agreement with another study in which approximately
89.5% of CD44s- negative pNTs were associated with the
unfavorable prognostic INPC system in comparison with
CD44s-positive tumors (approximately 65.5%) (P <0.05)
[37]. Several other groups have shown the same correlation
[32,35]. Therefore, absence of expression of CD44s can be
seen in the more immature peripheral neuroblastic tumors,
which correspond with the worst prognostic type based on
the modified Shimada system [6].
Cell adhesion is the condition sine qua non for the de-
velopment of multicellular organisms. Cell migration,
under physiological conditions, is the most importantduring embryogenesis, in tissue remodelling, wound
healing and leukocyte migration [38]. Cell adhesion and
migration are critical steps in cancer progression.
Simplistically, metastasis is depicted as the sequential
dissociation of tumor cells from the primary tumor, mi-
gration of the dissociated cells into and through normal
tissue, intravasation, survival in circulation, extravasation,
migration into and through extracellular matrices, tumor
cell proliferation, or, for tumor cells with high invasive
potential, proliferation, invasion, and uncontrolled pro-
gression at this and/or multiple other sites [38,39]. In
neuroblastic tumors, metastases are found mainly in the
bone marrow, bone and lymph nodes [3], however, other
less frequent secondary sites such as the liver, kidneys,
lungs and even the heart have been reported [40]. Many
cell adhesion molecules including integrins, cadherins,
immunoglobulin (Ig)-like CAMs, selectins, miscellaneous
others and CD44, have been reported to be involved in
each of these steps of the metastatic process and to be
expressed by primary neuroblastoma cells or cell lines
and associated with a given function or phenotype in this
cell type [39].
The role of CD44 adhesion glycoprotein in the evolu-
tion and progression of cancer has received a lot of at-
tention in recent years [38,41]. In view of the fact that
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lular matrix and CD44 is the major receptor for HA
[19], it is not surprising that CD44 plays a main role in
HA adhesion and crawling along the HA matrix thereby
providing a mechanism by which CD44 could influence
adhesion and de-adhesion to the extracellular matrix
[21]. It is believed that elevated HA levels form a less
dense matrix and consequently enhance cell motility as
well as invasive ability into other tissues [19]. The HA–
CD44 interactions have a central role in receptor tyro-
sine kinase (RTK)-induced activation of anti-apoptotic
pathways and actively promote tumor cells and possibly
cancer-initiating cell survival through their associations
with multidrug resistance genes [40]. Importantly, acti-
vation of signalling pathways initiated by the tumor
matrix could be inhibited by HA degradation, by compe-
tition with small HA fragments, by CD44 blockade or by
CD44 knockdown [41].
In most cancers, the dysregulated expression of CD44
is not the result of CD44 mutations. Instead, genes that
are implicated in promoting carcinogenesis control the
patterns of CD44 expression in cancer cells. Alternative
splicing, for example, is under the control of mitogenic
signals including the Ras-MAP kinase cascade. In
addition, the loss of different subunits of the SWI/SNF
chromatin remodeling complex, which are mutated in
numerous cancers, results in the loss of CD44 transcrip-
tion [21]. Aberrant CD44 expression is therefore inex-
tricably linked to genetic alterations that lead to tumor
growth and metastasis.
High expression of CD44 was observed on the surface
of skin, cervix, endometrium, stomach, colon and pros-
tate cancer cells [22,30]. It has been described in the lit-
erature that the presence of the CD44 molecule allows
neoplastic cells to metastasize. However, results from
other research have proved that it is not an increase but
a decrease of CD44 expression that appears as an un-
favorable prognostic factor in bladder cancer [42,43].
Our data reported a statistical significant association
(P = 0.013), between CD44 positive expression and the
absence of metastasis, on human neuroblastic cells. A
study by Valentiner et al. reported that expression of
CD44 was associated with a metastatic pattern of the
neuroblastoma cell lines engrafted in the SCID mice and
that CD44-negative neuroblastomas developed numer-
ous micrometastases in the lung interstitium while
CD44-positive neuroblastomas produced multicellular
metastases predominantly located in the intra- and
periarterial space of the lung [44]. These data have been
contradicted by a more recent report showing that the
CD44 negative SK-N-SH neuroblastoma cells were the
ones that infiltrated the bone marrow, spleen and liver
of transplanted animals, clearly indicating that the meta-
static ability of neuroblastoma cells is independent ofCD44 [45]. This study also showed that lack of CD44
expression was accompanied by lower levels of various
adhesion molecules, including CD49d (α4 integrin),
CD49e (α5 integrin) and CD29 (β1 integrin), as well as
ICAM1 and neural cell adhesion molecule NCAM [45]
which reduce adherence capacity and may enhance the
cells migratory ability and their propensity to form
metastases [46]. Therefore, the distinct cell adhesion
profile of CD44s negative cells suggests an enhanced
metastatic potential.
Conclusions
In conclusion, and as confirmed by multivariate analysis,
overexpression of CD44s could be regarded as a power-
ful predictor of the absence of tumor infiltration and of
the prognostically favorable subtypes of neuroblastic
tumors. Our results validate the prognostic value of
CD44s expression not only in neuroblastoma, as
reported in some previous works, but in all human
neuroblastic tumors and we recommend its integration
to predict metastasis and to target pathways for potential
therapeutic strategy.
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